{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARWR",
    "asset_name": "fazirsiran",
    "extracted_from": "ARWR Investment Thesis, Company Presentations",
    "extraction_date": "2026-02-05",
    "analyst_reviewed": true
  },
  "asset": {
    "name": "Fazirsiran",
    "alternate_names": ["ARO-AAT"],
    "company": "Arrowhead Pharmaceuticals",
    "ticker": "ARWR",
    "stage": "Phase 3",
    "modality": "RNAi (siRNA)",
    "ownership": "Partnered with Takeda",
    "one_liner": "First therapy addressing root cause of AATD liver disease with 96% Z-AAT reduction"
  },
  "target": {
    "name": "AAT",
    "full_name": "Alpha-1 Antitrypsin",
    "class": "Serine protease inhibitor",
    "pathway": "Protein misfolding / Liver toxicity",
    "biology": {
      "simple_explanation": "In Alpha-1 Antitrypsin Deficiency, the mutant Z-AAT protein misfolds and aggregates in hepatocytes instead of being secreted. This accumulation causes liver damage. By silencing AAT mRNA, fazirsiran prevents production of the toxic aggregates.",
      "pathway_detail": "The Z mutation (Glu342Lys) causes AAT to misfold in the ER. Instead of being secreted, Z-AAT polymerizes and accumulates in hepatocyte ER, triggering ER stress, autophagy impairment, and eventual cirrhosis.",
      "downstream_effects": [
        "96% reduction in Z-AAT protein",
        "Reduced hepatic aggregates",
        "Liver fibrosis improvement"
      ]
    },
    "why_good_target": {
      "clinical_validation": "No approved therapy for AATD liver disease; only lung disease treated with AAT augmentation",
      "rationale": "Silencing stops production at source; aggregates cleared over time",
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    }
  },
  "mechanism": {
    "type": "RNAi (siRNA) via TRiM platform",
    "delivery": "GalNAc-conjugated for hepatocyte targeting",
    "how_it_works": "Fazirsiran silences AAT mRNA in hepatocytes, reducing production of both normal and mutant Z-AAT protein. With reduced production, existing toxic aggregates are cleared, and liver damage halts or reverses.",
    "potency": {
      "z_aat_reduction": "96%"
    },
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "indications": {
    "lead": {
      "name": "Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD)",
      "patient_population": "~10-15% of AATD patients develop liver disease",
      "status": "Phase 3 (SEQUOIA)",
      "rationale": "No approved therapy; addresses root cause of liver damage"
    },
    "source": {
      "id": "arwr_thesis_2026",
      "verified": true
    }
  },
  "clinical_data": {
    "aroaat2002_phase2": {
      "trial_name": "AROAAT-2002",
      "nct_id": "NCT03946449",
      "design": {
        "type": "Open-label",
        "population": "AATD patients with liver disease"
      },
      "results": {
        "z_aat_reduction": "-96%",
        "fibrosis": "Histological fibrosis improvement observed",
        "interpretation": "Strong target engagement and early efficacy signal"
      },
      "source": {
        "id": "arwr_thesis_2026",
        "verified": true
      }
    },
    "ongoing_trials": [
      {
        "trial_name": "SEQUOIA Phase 2",
        "nct_id": "NCT03945292",
        "phase": "Phase 2",
        "indication": "AATD-LD",
        "status": "Completed"
      },
      {
        "trial_name": "SEQUOIA Phase 3",
        "nct_id": "NCT05677971",
        "phase": "Phase 3",
        "indication": "AATD Liver Disease",
        "status": "Recruiting",
        "data_expected": "2028"
      },
      {
        "trial_name": "SEQUOIA Extension",
        "nct_id": "NCT05899673",
        "phase": "Phase 3",
        "indication": "AATD-LD",
        "status": "Active, not recruiting"
      }
    ]
  },
  "investment_analysis": {
    "bull_case": [
      {
        "point": "Addresses root cause of AATD liver disease",
        "evidence": "96% Z-AAT reduction with histological fibrosis improvement",
        "confidence": "High"
      },
      {
        "point": "No approved therapy exists",
        "evidence": "AAT augmentation only treats lung disease, not liver",
        "confidence": "High - clear unmet need"
      },
      {
        "point": "Takeda partnership provides $1B+ potential milestones",
        "evidence": "Strong pharma partner with rare disease expertise",
        "confidence": "High"
      }
    ],
    "bear_case": [
      {
        "point": "AATD liver disease is rare",
        "evidence": "~10-15% of AATD patients develop liver disease",
        "counter_argument": "Orphan indication with high unmet need"
      },
      {
        "point": "Regulatory path unclear",
        "evidence": "May require clinical outcomes (not just Z-AAT reduction) for approval",
        "counter_argument": "Histology improvement in Phase 2 suggests pathway"
      },
      {
        "point": "Takeda controls development",
        "evidence": "Limited ARWR influence on timing and decisions",
        "counter_argument": "Milestone payments still meaningful"
      }
    ],
    "key_debates": [
      {
        "question": "Will Phase 3 SEQUOIA show sufficient fibrosis improvement for FDA approval?",
        "bull_view": "Phase 2 showed histological improvement; mechanism sound",
        "bear_view": "Long timeline (2028), regulatory uncertainty",
        "what_resolves_it": "SEQUOIA Phase 3 data"
      }
    ]
  },
  "competitive_landscape": [],
  "catalysts": [
    {
      "event": "SEQUOIA Phase 3 data",
      "timing": "2028",
      "importance": "Critical",
      "what_to_watch": "Fibrosis improvement, Z-AAT reduction, safety"
    }
  ],
  "partnership": {
    "partner": "Takeda",
    "upfront": "$300M",
    "milestones": "$1,040M",
    "received_to_date": "$340M",
    "royalties": "Tiered on net sales"
  },
  "sources": [
    {
      "id": "arwr_thesis_2026",
      "title": "ARWR Investment Thesis",
      "type": "Internal Analysis",
      "date": "2026-02-02"
    },
    {
      "id": "clinicaltrials",
      "title": "ClinicalTrials.gov",
      "type": "Clinical Trial Registry",
      "url": "https://clinicaltrials.gov/api/v2/studies"
    }
  ]
}
